| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/22/2006 | WO2006063700A1 1-arylpyrazoles and their use as pesticides |
| 06/22/2006 | WO2006063697A1 Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use |
| 06/22/2006 | WO2006063681A1 Use of substituted cyclopropane acid derivatives for producing drugs for use in the treatment of metabolic syndrome |
| 06/22/2006 | WO2006063666A1 Process for the preparation of galanthamine hydrobromide |
| 06/22/2006 | WO2006063639A1 Use of acetyl l-carnitine for the treatment of fibromyalgic syndrome |
| 06/22/2006 | WO2006063615A1 NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17β-HYDROXYSTEROID DEHYDROGENASE |
| 06/22/2006 | WO2006063610A1 Heteroaryl substituted diazabicyclononene derivatives |
| 06/22/2006 | WO2006063585A1 Triazole substituted aminobenzophenone compounds |
| 06/22/2006 | WO2006063526A1 Use of cymipristone for treating depression |
| 06/22/2006 | WO2006063515A1 Use of radix sanguisorbae and its extract for preparing medicament to increase rbc and hemoglobin |
| 06/22/2006 | WO2006063466A1 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors |
| 06/22/2006 | WO2006063462A1 Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| 06/22/2006 | WO2006063446A1 Methods of cardioprotection using dichloroacetate in combination with an inotrope |
| 06/22/2006 | WO2006063425A1 Expression vectors for treating bacterial infections |
| 06/22/2006 | WO2006063408A1 Compositions and methods for treating cardiovascular disorders |
| 06/22/2006 | WO2006063397A1 Determinants of sensitivity to chemotherapeutic agents |
| 06/22/2006 | WO2006063382A1 Treatment of solid cancers |
| 06/22/2006 | WO2006052555A3 Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 06/22/2006 | WO2006051314A3 Guanidine derivatives as inhibitors of ddah |
| 06/22/2006 | WO2006049657A3 Insulin secretion by anthocyanins and anthocyanidins |
| 06/22/2006 | WO2006044869A8 Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| 06/22/2006 | WO2006044359A3 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 06/22/2006 | WO2006044077A3 Controlled release composition with semi-permeable membrane and poloxamer flux enhancer |
| 06/22/2006 | WO2006042289A3 Substituted biaryl quinolin-4-ylamine analogues |
| 06/22/2006 | WO2006040047A3 Diagnostics and therapeutics for diseases associated with rho/rac-interacting citron kinase (cit) |
| 06/22/2006 | WO2006038226A3 Process for making a highly compressible controlled delivery compositions of metformin |
| 06/22/2006 | WO2006036883A3 Imidazo{4,5-b}pyrazinone inhibitors of protein kinases |
| 06/22/2006 | WO2006036625A3 Encapsulated pharmaceutical agents |
| 06/22/2006 | WO2006031471A3 Liposomal vectors |
| 06/22/2006 | WO2006030437A3 Novel tellurium compounds and their use as immunomodulators |
| 06/22/2006 | WO2006028904A9 Quinazolines useful as modulators of ion channels |
| 06/22/2006 | WO2006026430A3 Cyclopamine analogues and methods of use thereof |
| 06/22/2006 | WO2006026380A3 Geranylgeranyl pyrophosphate synthase inhibitors |
| 06/22/2006 | WO2006024741A3 Hybrid qa molecules wherein q is an aminoquinoline and a is an antibiotic residue, their synthesis and their uses as antibacterial agent |
| 06/22/2006 | WO2006024488A3 Medical stent provided with inhibitors of atp synthesis |
| 06/22/2006 | WO2006023891A3 Ligand-dependant activation of nur77 and uses thereof |
| 06/22/2006 | WO2006023562B1 5-[3-(4-Benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase |
| 06/22/2006 | WO2006016247A3 Lysis/resealing process and device for incorporating an active ingredient in erythrocytes |
| 06/22/2006 | WO2006015283A3 Treatment of benign prostatic hyperplasia |
| 06/22/2006 | WO2006013049A3 Benzyloxy derivatives as maob inhibitors |
| 06/22/2006 | WO2006008008A3 Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a) |
| 06/22/2006 | WO2006007508A3 Compounds and methods for treating diabetic vascular diseases |
| 06/22/2006 | WO2006003013A3 NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17β-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1 |
| 06/22/2006 | WO2006000567A3 Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function |
| 06/22/2006 | WO2005123135A8 Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide |
| 06/22/2006 | WO2005123079A3 Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| 06/22/2006 | WO2005121327A3 Biosynthetic gene cluster for the production of a complex polyketide |
| 06/22/2006 | WO2005116210A3 Stat6 inhibiting sirna and shrna for use in the treatment of allergic diseases, pathological changes of the respiratory system and cancer |
| 06/22/2006 | WO2005110367A3 Sustained release intraocular implants and methods for preventing retinal dysfunction |
| 06/22/2006 | WO2005105213A3 Indole and azaindole derivatives with antitumor action |
| 06/22/2006 | WO2005102362A8 Use of chondroitin sulphate e (cs-e ) for the treatment diseases or conditions related to collagen fibril formation. |
| 06/22/2006 | WO2005102287A3 Pharmaceutical compositions for acute glucocorticoid therapy |
| 06/22/2006 | WO2005101004A8 Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1) |
| 06/22/2006 | WO2005085867A8 Screening method for emulators of neural activity and digestive system using gpr35 |
| 06/22/2006 | WO2005084671A3 Combination of voriconazole and an antifungal cyp2c19 inhibitor |
| 06/22/2006 | WO2005080397A8 Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders |
| 06/22/2006 | WO2005079851A3 Dopamine-agonist combination therapy with sedatives for improving sleep quality |
| 06/22/2006 | WO2005077941A3 Candesartan cilexetil polymorphs |
| 06/22/2006 | WO2005058024A3 Method of treating fish and crustaceans with a tellurium based immunomodulator |
| 06/22/2006 | WO2005054428A3 Method for inhibiting cancer cells |
| 06/22/2006 | WO2005047291A9 Method for the catalytic production of hydrocodone and hydromorphone |
| 06/22/2006 | WO2005046615A3 Compositions for treatment of central nervous system mediated disorders |
| 06/22/2006 | WO2005044228A3 Compositions comprising cyclohexylamines and aminoadamantanes |
| 06/22/2006 | WO2005041968A3 Once-a-day, oral, controlled-release, oxycodone dosage forms |
| 06/22/2006 | WO2005025487A9 Oligonucleotides targeting prion diseases |
| 06/22/2006 | WO2005020884A3 Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
| 06/22/2006 | WO2005004805A3 Thermally stable crystalline epirubicin hydrochloride and method of making the same |
| 06/22/2006 | WO2004071419A3 Methods and compositions for modulating glutamate transport activity in the nervous system |
| 06/22/2006 | WO2003061655A8 2-aminothiazole allosteric enhancers of a1 adenosine receptors |
| 06/22/2006 | US20060136146 Modulators of ribosomal function and identification thereof |
| 06/22/2006 | US20060135906 Iontophoretic device and method for administering immune response-enhancing agents and compositions |
| 06/22/2006 | US20060135812 Thiol-based NAALADase inhibitors |
| 06/22/2006 | US20060135808 Novel intermediates for use in retinoid synthesis |
| 06/22/2006 | US20060135796 Antiangiogenic agents |
| 06/22/2006 | US20060135794 Process for recovery of plant sterols from by-product of vegetable oil refining |
| 06/22/2006 | US20060135778 Pesticidal 5-(acylamino) pyrazole derivatives |
| 06/22/2006 | US20060135776 4-Cyanopyrazole-3-carboxamide derivatives, preparation, and application thereof |
| 06/22/2006 | US20060135769 Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives |
| 06/22/2006 | US20060135765 Antineoplastic ether lipid compounds |
| 06/22/2006 | US20060135762 Preventing the deposits of amyloid protein, treating neurodegenerative disease, Alzheimer's disease and Down's Syndrome; {[carbamoyl]cycloalkyl}-N-(2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))- or (2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))-carboxamide |
| 06/22/2006 | US20060135746 Peptide used to inhibit the binding of HIV to cell surface receptor CD4 |
| 06/22/2006 | US20060135625 Method of administering split doses of a vascular targeting agent |
| 06/22/2006 | US20060135624 Natural compound useful for treating diabetes, its preparation and use |
| 06/22/2006 | US20060135623 Decrease in oxidative stress status through the administration of natural products and pharmaceutical drugs |
| 06/22/2006 | US20060135622 Amino alcohol derivative, addition salt thereof, and immunosuppressant |
| 06/22/2006 | US20060135621 Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
| 06/22/2006 | US20060135620 Novel compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
| 06/22/2006 | US20060135619 2-[(3-chloro-4-hydroxybenzoyl)amino]-N-[2-(2-methoxyphenyl)ethyl]-5-phenoxybenzamide; therapeutic use as anti-cancer agents, as well as other therapeutic agents, for example, as anti-fertility agents |
| 06/22/2006 | US20060135618 Medicine comprising a thiourea for use as depigmenting agent or anti-mutagenic and anti-carcinogenic agent |
| 06/22/2006 | US20060135617 Process for producing optically active flurbiprofen |
| 06/22/2006 | US20060135616 Aromatic compositions for the inhibition of exoprotein production from gram positive bacteria |
| 06/22/2006 | US20060135615 Deuterated catecholamine derivatives and medicaments comprising said compounds |
| 06/22/2006 | US20060135614 Novel compounds |
| 06/22/2006 | US20060135613 Carboxamides derivatives |
| 06/22/2006 | US20060135612 Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| 06/22/2006 | US20060135611 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
| 06/22/2006 | US20060135610 Cardiovascular compositions |
| 06/22/2006 | US20060135609 Ophthamological drugs |
| 06/22/2006 | US20060135608 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia |
| 06/22/2006 | US20060135607 Drug for improving prognosis for subarachnoid hemorrhage |